Ardelyx, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2022. Ardelyx is a biopharmaceutical company developing and commercializing medicines. It began U.S. sales of IBSRELA for IBS-C in March 2022; XPHOZAH for hyperphosphatemia remained unapproved.
Financial performance and position
Amounts below are in millions of dollars except per-share data. The quarter reflects early IBSRELA sales and continued operating losses.
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Total revenue | $0.468 | $6.582; down 92.9% |
| IBSRELA product sales, net | $0.450 | No product sales |
| Operating expenses | $28.275 | $38.587; down 26.7% |
| Operating loss | $27.807 | $32.005 |
| Net loss | $28.071 | $33.155 |
| Net loss per share | $0.21 | $0.34 |
| Net cash used in operations | $27.620 | $44.217 |
| Cash, cash equivalents and short-term investments at quarter-end | $89.704 | $116.689 at December 31, 2021 |
Revenue fell mainly because the prior-year quarter included a $5.0 million KKC development milestone and $1.454 million of collaborative development revenue; neither recurred. R&D expense decreased 56.7% to $8.851 million, reflecting lower clinical and manufacturing costs and the prior restructuring. Selling, general and administrative expense increased 12.9% to $19.339 million as Ardelyx built its commercial organization. Cost of revenue was $0.085 million; the filing does not provide a meaningful margin comparison given the newly launched product and prior expensing of some inventory costs.
Operating cash use improved year over year, but liquid funds declined by $26.985 million during the quarter. Financing included $27.5 million gross initial borrowing under the new loan, repayment of the prior loan, and $5.921 million net ATM proceeds. Ardelyx sold 5.9 million shares in the quarter at an average $1.02 per share. After quarter-end, it sold 8.3 million additional shares for $9.0 million gross proceeds. Common shares outstanding were 136.3 million at March 31 and 144.6 million at May 2.
Total liabilities were $65.218 million at March 31. The $27.5 million funded senior secured loan carried a floating rate of 7.95% plus the greater of 0.10% or the one-month benchmark rate, with interest-only payments permitted through March 2024 and maturity in March 2027. The company classified the loan as current because of its going-concern assessment and a lender material-adverse-change provision. A further $22.5 million may be borrowed only if specified FDA-approval and product-revenue conditions are met.
Material developments and outlook
- Liquidity and going concern: Management stated that March 31 cash and investments alone were insufficient to fund operating plans for the next 12 months and that substantial doubt existed about the company’s ability to continue as a going concern. Plans include IBSRELA sales, potential collaboration milestones and payments, capital-market access, and spending reductions; success is not assured.
- XPHOZAH regulatory appeal: The FDA issued a Complete Response Letter in July 2021, citing a treatment effect of small and unclear clinical significance. After an appeal denial, the FDA’s Office of New Drugs indicated it intended to bring the NDA to an advisory committee. No approval is assured; potential additional loan funding also depends on FDA approval by December 31, 2022 and revenue milestones.
- KKC amendment: In April 2022, Ardelyx agreed to reduce future Japanese royalties in exchange for up to $40 million in two contingent payments tied to KKC’s application filing and regulatory approval. These are potential, not guaranteed, receipts.
- Other pipeline: RDX013’s Phase 2 study showed potassium reductions after eight days but failed its primary endpoint at four weeks. Further study and a new formulation were under consideration, subject to available resources. Ardelyx expected to continue RDX020 discovery using third parties after eliminating its internal research organization.
- Listing and dilution: Ardelyx regained Nasdaq’s minimum bid-price compliance in March, but disclosed that its share price was again below $1 on April 8. It was considering options including a reverse stock split. Further equity issuance could dilute shareholders.
- Legal matters: Securities class actions and related derivative suits concerning prior statements about tenapanor were pending; derivative actions were stayed. Management considered the claims without merit and recorded no related contingency accrual.
Other significant risks include dependence on successful IBSRELA commercialization and adequate reimbursement, uncertain XPHOZAH approval and market access, reliance on third-party manufacturers, loan covenants and default provisions, competition, and continued operating losses. The filing states that results for the quarter are not necessarily indicative of full-year results.
Most important facts for investors to verify
- Actual IBSRELA prescription demand, net sales, reimbursement coverage, and the impact of rebates, discounts, and returns as launch history develops.
- Advisory committee timing and recommendation, FDA’s subsequent response, and whether XPHOZAH can obtain approval.
- Cash burn and financing runway, including whether collaboration payments or additional capital become available and whether cost reductions are implemented.
- Whether the conditions for the additional $22.5 million loan tranche are met, and the effects of secured debt, covenants, and variable interest costs.
- Nasdaq bid-price compliance, any reverse-split action, and further share issuance or dilution.
- Progress and financial terms of the KKC amendment, including whether either contingent payment is earned and the resulting lower royalty economics.
- Developments in the securities and derivative litigation and any resulting costs or liabilities.